SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma ...

Roche (RHHBY) announced that the FDA has approved a label expansion of the asthma drug Xolair (omalizumab).The regulatory body approved the drug for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged one year and older with IgE-mediated food allergy.The FDA approval is based on positive data from the late-stage OUtMATCH study, which evaluated Xolair in patients aged between one and 55 years who are all ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods they are all ...

Cristina Arias/Cover via Getty Images Description The Swiss company Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) is one of the most well-recognized brands in the pharmaceutical sector. It has a CHF 187 billion market capitalization and annual revenues of CHF 58.7 billion (2023 data). With a 2.7% weight, it is the tenth largest company by weight within the MSCI world healthcare index. msci world health care sector weight (MSCI World) The company has a strong international presence, as it generates 48% of ...

Roche Holding AG (OTCQX:RHHBY) February 01, 2024, 09:30 AM ET Thomas Schinecker - CEO Roche Group Matt Sause - CEO Roche Diagnostics Bruno Eschli - Head of IR Charlie Mabbutt - Morgan Stanley Simon Baker - Redburn Sachin Jain - Bank of America John Priestner - JP Morgan Ladies and gentlemen, welcome to Roche's Full Year Results Webinar 2023. My name is Hendrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. I would like to inform you that all participants ar ...

Roche’s (RHHBY) performance in 2023 was impacted by a sharp decline in COVID-19-test sales and exchange rate fluctuations, even though newer drugs and the diagnostics base business maintained their growth.Roche has lost 8.3% in the past six months against the industry’s growth of 11.2%.Image Source: Zacks Investment ResearchSales in 2023 came in at $65.4 billion, missing the Zacks Consensus Estimate of $68.2 billion. Earnings per American Depositary Receipt of $2.58 also missed the Zacks Consensus Estimate ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to ...

Roche (RHHBY) announced that the European Commission has granted marketing authorization to subcutaneous ("SC”) (under the skin) injection of the cancer immunotherapy drug Tecentriq (atezolizumab).The authorization applies to all approved indications of intravenous (“IV”) formulation of Tecentriq and makes it the European Union’s first programmed death ligand-1 (PD-L1) cancer immunotherapy for subcutaneous injection.Tecentriq IV is approved for the treatment of a certain type of early-stage (adjuvant) non-s ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth ...

Roche Holding AG (OTCQX:RHHBY) Q3 2023 Earnings Conference Call October 19, 2023 8:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer Roche Group Teresa Graham - Chief Executive Officer Roche Pharmaceuticals Matthew Sause - CEO Roche Diagnostics Alan Hippe - Chief Financial and Information Officer Bruno Eschli - Head of Investor Relations Conference Call Participants Mark Purcell - Morgan Stanley Luisa Hector - Berenberg Andrew Baum - Citi Steve Scala - Cowen Emmanuel Papadakis - Deut ...